| Literature DB >> 35650276 |
Emily Latacz1, Diederik Höppener2, Ali Bohlok3, Vincent Donckier3, Peter M Siegel4,5, Raymond Barnhill6,7, Marco Gerling8,9, Cornelis Verhoef2, Peter B Vermeulen10, Sophia Leduc11, Sébastien Tabariès4, Carlos Fernández Moro12,13, Claire Lugassy6, Hanna Nyström14,15, Béla Bozóky13, Giuseppe Floris16,17, Natalie Geyer8, Pnina Brodt18, Laura Llado19, Laura Van Mileghem1, Maxim De Schepper11, Ali W Majeed20, Anthoula Lazaris21, Piet Dirix1, Qianni Zhang22, Stéphanie K Petrillo21, Sophie Vankerckhove3, Ines Joye1, Yannick Meyer2, Alexander Gregorieff21,23,24, Nuria Ruiz Roig25,26,27, Fernando Vidal-Vanaclocha28, Larsimont Denis29, Rui Caetano Oliveira30,31,32, Peter Metrakos21, Dirk J Grünhagen2, Iris D Nagtegaal33, David G Mollevi26,34, William R Jarnagin35, Michael I D'Angelica35, Andrew R Reynolds36, Michail Doukas37, Christine Desmedt11, Luc Dirix1.
Abstract
The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver metastases were established in 2017. Since then, numerous studies have applied these guidelines, have further substantiated the potential clinical value of the HGPs in patients with liver metastases from various tumour types and are starting to shed light on the biology of the distinct HGPs. In the present guidelines, we give an overview of these studies, discuss novel strategies for predicting the HGPs of liver metastases, such as deep-learning algorithms for whole-slide histopathology images and medical imaging, and highlight liver metastasis animal models that exhibit features of the different HGPs. Based on a pooled analysis of large cohorts of patients with liver-metastatic colorectal cancer, we propose a new cut-off to categorise patients according to the HGPs. An up-to-date standard method for HGP assessment within liver metastases is also presented with the aim of incorporating HGPs into the decision-making processes surrounding the treatment of patients with liver-metastatic cancer. Finally, we propose hypotheses on the cellular and molecular mechanisms that drive the biology of the different HGPs, opening some exciting preclinical and clinical research perspectives.Entities:
Mesh:
Year: 2022 PMID: 35650276 PMCID: PMC9470557 DOI: 10.1038/s41416-022-01859-7
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 9.075